Improvement in tardive dyskinesia after muscimol therapy.
Muscimol, thought to be a agonist of gamma-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia. At oral dose levels from 5 to 9 mg, involuntary movements were consistently attenuated, usually in the absence of sedation. These results support the view that pharmacologic attempts to stimulate GABA-mediated synaptic transmission may afford symptomatic relief to patients with tardive dyskinesia.
D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects; D004298:Dopamine / Q000502:physiology; D004341:Drug Evaluation; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005116:Extrapyramidal Tracts / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009118:Muscimol / Q000494:pharmacology / Q000627:therapeutic use*; D010080:Oxazoles / Q000627:therapeutic use*; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy; D013268:Stimulation, Chemical; D009435:Synaptic Transmission / Q000187:drug effects; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology / Q000502:physiology
D014150:Antipsychotic Agents; D010080:Oxazoles; D011954:Receptors, Dopamine; D009118:Muscimol; D005680:gamma-Aminobutyric Acid; D004298:Dopamine